Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Trius Therapeutics Reveals Plans for IPO, SpectraScience Raises $4.3M, Sequenom Tightens its Belt, & More San Diego Life Sciences News
|
Denise Gellene |
11/12/09 |
San Diego
|
|
Rib-X Antibiotic Passes Clinical Trial, Hopes to Snag Partner
|
Luke Timmerman |
08/05/09 |
Boston
|
|
Trius Approaches Next Stage in Drug Development, China Partnerships a Hot Topic at CalAsia, Lpath Headed to Critical Juncture, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/18/09 |
San Diego
|
|
Trius Looks to Cut a Deal, Gears Up For Final Stage of Trials with New Antibiotic
|
Luke Timmerman |
06/12/09 |
San Diego
|
|
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/11/09 |
San Diego
|
|
Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test
|
Luke Timmerman |
06/08/09 |
San Diego
|
|
Optimer Rides Investment See-Saw With Promising Drug for “C.diff” Infections
|
Luke Timmerman |
06/05/09 |
San Diego
|
|
Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections
|
Luke Timmerman |
03/30/09 |
Seattle
|
|
Calixa Passes Key Safety Test in Clinical Trial of New Antibiotic
|
Luke Timmerman |
03/24/09 |
San Diego
|
|
EU Spurns Gilead’s Aztreonam
|
Luke Timmerman |
03/20/09 |
Seattle
|
|
Optimer Raises $32.9M in Stock Offering
|
Luke Timmerman |
03/05/09 |
San Diego
|
|
Novophage Forming to Combat Antibiotic Resistance with Engineered Viruses
|
Ryan McBride |
03/05/09 |
Boston
|
|
Optimer To Seek EU Approval
|
Luke Timmerman |
03/02/09 |
San Diego
|
|
Oscient to Shed 32% of Workers
|
Ryan McBride |
02/12/09 |
Boston
|
|
Mpex Pharma Lands $27.5M in Fourth Round
|
Ryan McBride |
02/10/09 |
San Diego
|
|
Forma Forms Antibiotic-Discovery Partnership with Cubist
|
Ryan McBride |
01/26/09 |
Boston
|
|
Rib-X Raises $25M in Debt Financing, Reveals Final Results of Antibiotic Trial
|
Ryan McBride |
01/26/09 |
Boston
|
|
Optimer’s Second Drug, for Traveler’s Diarrhea, Follows Fast Behind Lead “C. Diff” Antibiotic
|
Luke Timmerman |
01/23/09 |
San Diego
|
|
Targanta Gets $42M Buyout Offer From NJ Drug Firm
|
Ryan McBride |
01/13/09 |
Boston
|
|
Targanta Cuts 75 Percent of Staff
|
Wade Roush |
12/18/08 |
Boston
|
|
FDA Declines Approval of Targanta Antibiotic
|
Ryan McBride |
12/09/08 |
Boston
|
|
Rib-X Reveals “Positive” Antibiotic Data
|
Ryan McBride |
12/08/08 |
Boston
|
|
Optimer Sharpens Up Commercial Game Plan, After “C.Diff” Drug Success
|
Luke Timmerman |
12/05/08 |
San Diego
|
|
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter
|
Luke Timmerman |
11/25/08 |
Boston
|
|
Optimer Shares Skyrocket, as Drug Halts Deadly Bacterial Infection in Trial
|
Luke Timmerman |
11/10/08 |
San Diego
|
|
Optimer, Developer of Drug For “C. Diff” Bacteria, Awaits Pivotal Results
|
Luke Timmerman |
10/23/08 |
San Diego
|
|
Trius Therapeutics Wins $28M Contract From NIH For Bioterror Antibiotics
|
Luke Timmerman |
10/22/08 |
San Diego
|
|
Trius Therapeutics, Developer of Antibiotic Against MRSA, Taking On Pfizer’s Zyvox
|
Luke Timmerman |
10/20/08 |
San Diego
|
|
Targanta Preps For FDA Advisory Panel on New Antibiotic
|
Luke Timmerman |
10/14/08 |
Boston
|
|
Rib-X Pharma, and Its Lead Antibiotic, Gear Up for Prime Time
|
Ryan McBride |
10/02/08 |
Boston
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
